About this condition
Systemic sclerosis (scleroderma) is a chronic autoimmune disease characterized by abnormal collagen deposition affecting skin, blood vessels, and internal organs. The disease ranges from limited cutaneous (formerly CREST) involvement to diffuse systemic disease with rapid progression and major organ involvement: interstitial lung disease, pulmonary hypertension, renal crisis, esophageal dysmotility, cardiac involvement.
Listing 14.04 follows the standard immune-disorder structure. Path A requires involvement of at least one organ system to at least moderate severity AND at least two constitutional symptoms. Path B requires repeated manifestations with at least two constitutional symptoms AND a marked limitation in daily living, social functioning, or task completion. Scleroderma claims often qualify under one of these paths when documentation is comprehensive.
What the SSA Listing requires (Listing 14.04)
What wins this case at hearing in Colorado
-
Diagnostic serology
ANA (typically positive in scleroderma), anti-centromere antibody (limited cutaneous), anti-Scl-70 (diffuse cutaneous), anti-RNA polymerase III. Skin biopsy if performed.
-
Organ-involvement documentation
Pulmonary: HRCT showing interstitial lung disease, PFTs with reduced DLCO/FVC. Cardiac: echo showing pulmonary hypertension or cardiac involvement. Renal: history of scleroderma renal crisis. GI: esophageal manometry showing dysmotility, evidence of GERD or strictures.
-
Skin and extremity findings
Modified Rodnan skin score documentation, photographic records of skin changes, Raynaud’s phenomenon documentation, digital ulcer history, capillaroscopy findings.
-
Rheumatologist treatment records
Records of disease-modifying therapy (mycophenolate, cyclophosphamide for ILD; ACE inhibitors for renal protection; calcium channel blockers for Raynaud’s), and disease activity assessments.
-
Functional capacity statement
Rheumatologist’s opinion on workday capacity: cold-exposure restrictions for Raynaud’s, dexterity limits from finger/hand skin changes, exertion tolerance with pulmonary involvement, GI symptom impact on meal scheduling.
Colorado-specific factors
Colorado has specialized scleroderma care at UCHealth Anschutz (rheumatology and pulmonary collaboration) and National Jewish Health (pulmonary expertise for scleroderma-ILD). Documentation tends to be detailed for scleroderma patients accessing these specialty programs.
One Colorado-specific issue worth raising: high-altitude environments can stress patients with pulmonary involvement and Raynaud’s phenomenon. The cold winters and outdoor exposure typical of Colorado work environments can be incompatible with scleroderma symptoms — useful context for the vocational analysis.
What disqualifies a claim (honestly)
Scleroderma cases that may need additional development: limited cutaneous scleroderma (formerly CREST) without organ involvement; isolated Raynaud’s phenomenon without systemic features; very early-stage diffuse scleroderma before organ involvement develops. These can still qualify in some scenarios but require careful documentation of constitutional symptoms and functional impact.
Frequently asked questions about SSDI for Scleroderma (Systemic Sclerosis) in Colorado
I have limited scleroderma (CREST). Does that qualify the same way?
Limited cutaneous scleroderma can qualify under Listing 14.04 when there’s organ involvement (most commonly pulmonary hypertension, GI involvement, or progressive skin changes) plus constitutional symptoms. The “limited” label refers to skin involvement distribution, not to disease severity — many limited scleroderma patients have significant systemic complications.
My main problem is Raynaud's and ulcers on my fingers. Is that enough?
Raynaud’s alone usually isn’t enough — but severe Raynaud’s with documented digital ulcerations, frequent infections, and fine-motor impairment can support a claim, particularly in combination with other scleroderma manifestations. Documentation of cold-exposure restrictions and how they affect work options is important.
I have scleroderma-related lung disease. Does that affect my case?
Significantly — pulmonary involvement is one of the strongest scleroderma claim drivers. Scleroderma-related interstitial lung disease (ILD) can be evaluated under both Listing 14.04 (immune system) and Listing 3.00 (respiratory) — particularly Listing 3.02 for chronic respiratory disorders with reduced PFTs. PFTs with DLCO under 40% predicted are particularly persuasive.
How long does a scleroderma SSDI claim take in Colorado?
18 to 28 months from initial application through ALJ hearing in Colorado in 2026. Strong cases with multi-organ involvement sometimes approve at initial application or reconsideration without requiring an ALJ hearing.